Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.65 |
| ▸ | RELA | Q04206 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | HPGDS | O60760 | 11/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17055377 | 0.95 | NPC1 (0.67) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL10091200 | 0.95 | NPC1 (0.67) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL15599291 | 0.87 | NPC1 (0.48) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL12628225 | 0.87 | L3MBTL1 (0.59) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL16602145 | 0.85 | NPC1 (0.54) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL21105334 | 0.83 | HPGDS (0.53) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL17055369 | 0.83 | CLK4 (0.54) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL13910154 | 0.82 | NPC1 (0.75) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL11933090 | 0.82 | NPC1 (0.75) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL30123307 | 0.82 | NPC1 (0.45) | NPC1RAB9ANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240244946-A1 | ORGANIC LIGHT EMITTING DIODE COMPRISING ORGANOMETALLIC COMPOUND AND PLURALITY OF HOST MATERIALS | LG DISPLAY CO., LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-20240244946-A1 | ORGANIC LIGHT EMITTING DIODE COMPRISING ORGANOMETALLIC COMPOUND AND PLURALITY OF HOST MATERIALS | LG DISPLAY CO., LTD. (KR) | 2024-07-18 | — | — | US | disclosed |
| US-20240109842-A1 | ACRYLAMIDE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-04 | — | — | US | disclosed |
| WO-2024059186-A1 | N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-21 | — | — | WO | disclosed |
| US-11917843-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-11818932-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-14 | — | — | US | disclosed |
| US-20230363260-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-09 | — | — | US | disclosed |
| US-11807654-B2 | Organometallic compound, organic light-emitting device including organometallic compound, and diagnostic composition including organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-11-07 | — | — | US | disclosed |
| US-20230337522-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230337522-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-10-19 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20100328600-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-30 | — | — | US | disclosed |
| US-7695777-B2 | cyclohexenylene compounds which have a phenylene ring both fluoro and chloro substituted; wide temperature range; heat and light stable; small viscosity, large optical anisotropy; suitable negative dielectric anisotropy and excellent compatibility with other liquid crystal compounds; short response times | CHISSON CORPORATION (JP) | 2010-04-13 | — | — | US | disclosed |
| US-7510749-B2 | Difluorobenzene derivative, alkenyl, cyclohexenyl; increased voltage holding ratio; high clearing point, low minimum temperature liquid crystal phase, enhanced temperature range of nematic phase; display device useful in wide temperature range; small viscosity, large elastic constant, fast response time | CHISSO CORPORATION (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20080075891-A1 | cyclohexenylene compounds which have a phenylene ring both fluoro and chloro substituted; wide temperature range; heat and light stable; small viscosity, large optical anisotropy; suitable negative dielectric anisotropy and excellent compatibility with other liquid crystal compounds; short response times | CHISSO CORPORATION | 2008-03-27 | — | — | US | disclosed |
| US-20080063814-A1 | Difluorobenzene derivative, alkenyl, cyclohexenyl; increased voltage holding ratio; high clearing point, low minimum temperature liquid crystal phase, enhanced temperature range of nematic phase; display device useful in wide temperature range; small viscosity, large elastic constant, fast response time | CHISSO CORPORATION | 2008-03-13 | — | — | US | disclosed |
| US-5977075-A | N-aroylamino acid amides as endothelin inhibitors | NOVARTIS AG (CH) | 1999-11-02 | — | — | US | disclosed |
| EP-0821670-A1 | N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS | Novartis AG (CH) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996033170-A1 | N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS | NOVARITS AG (CH) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | NPC1 1631/4885RAB9A 972/4885NFKB1 3975/4885 |
| US-20240244946-A1 | ORGANIC LIGHT EMITTING DIODE COMPRISING ORGANOMETALLIC COMPOUND AND PLURALITY OF HOST MATERIALS | GPX1, PER2, SOD1 | NPC1 3426/4885RAB9A 2846/4885NFKB1 1709/4885 |
| US-20080063814-A1 | Difluorobenzene derivative, alkenyl, cyclohexenyl; increased voltage holding ratio; high clearing point, low minimum temperature liquid crystal phase, enhanced temperature range of nematic phase; display device useful in wide temperature range; small viscosity, large elastic constant, fast response time | POU2F2, HCN2, POU2F1 | NPC1 981/4885RAB9A 2373/4885NFKB1 2249/4885 |
| US-20230337522-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | L1CAM, EML4, LBR | NPC1 1803/4885RAB9A 1415/4885NFKB1 1282/4885 |
| US-11917843-B2 | Organic electroluminescent materials and devices | OCIAD2, OCIAD1, AOC2 | NPC1 2329/4885RAB9A 1804/4885NFKB1 2010/4885 |
| US-20080075891-A1 | cyclohexenylene compounds which have a phenylene ring both fluoro and chloro substituted; wide temperature range; heat and light stable; small viscosity, large optical anisotropy; suitable negative dielectric anisotropy and excellent compatibility with other liquid crystal compounds; short response times | CNKSR1, CLCN2, LEF1 | NPC1 3055/4885RAB9A 948/4885NFKB1 2377/4885 |
| US-11807654-B2 | Organometallic compound, organic light-emitting device including organometallic compound, and diagnostic composition including organometallic compound | L1CAM, FOXM1, MEN1 | NPC1 2803/4885RAB9A 3177/4885NFKB1 1438/4885 |
| US-20100328600-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, MARK3, CCND3 | NPC1 3594/4885RAB9A 2204/4885NFKB1 3532/4885 |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | NPC1 1614/4885RAB9A 710/4885NFKB1 3524/4885 |
| US-20240109842-A1 | ACRYLAMIDE COMPOUNDS | HPGDS, MYADM, ACR | NPC1 4406/4885RAB9A 3162/4885NFKB1 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.